New pill timing may help heart failure patients flush salt after meals

NCT ID NCT06995144

Completed Disease control Sponsor: Sarfez Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an extended-release version of the diuretic torsemide helps heart failure patients get rid of more salt after lunch compared to the standard immediate-release version. Twenty adults with stable heart failure took both forms in a random order, and researchers measured their urine sodium levels. The goal is to see if a longer-acting pill can improve fluid balance without extra side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: torsemide (extended-release and immediate-release tablets)
What this could lead to: If it works, this could lead to a better-timed diuretic that helps heart failure patients excrete more salt after meals, potentially improving fluid control.
What could go wrong: This is a small, early-phase crossover study with only 20 participants, so results may not apply broadly. The benefit is modest—improving timing of sodium excretion—not a cure or major outcome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome Edema heart failure Hypernatremia pulmonary edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EDEMA FLUID OVERLOAD HEART FAILURE PULMONARY CONGESTION

Contacts and locations

Locations

Future Life Clinical Trials

Miami, Florida, 33169, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.